Company: DRTSW
Filing Date: 2025-06-23
Form Type: F-3
Source: 0001213900-25-056744
Chunk: 15

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-06-23
Form: F-3
Chunk 15
---
 the United States. In this prospectus and in the documents and information incorporated by reference in this prospectus, we have taken advantage of certain of the reduced reporting requirements as a result of being an emerging growth company and a foreign private issuer. Accordingly, the information contained in this prospectus and in the documents incorporated by reference in this prospectus may be different than the information you receive from other public companies in which you hold equity securities.

<div align='center'>4</div>

THE OFFERING

| Securities that may be offered and sold from time to time by the Selling Shareholders |     | Up to 3,463,202 ordinary shares.                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Offering prices of the ordinary shares                                                |     | The securities offered by this prospectus may be offered and sold at prevailing market prices, privately negotiated prices or such other prices as the Selling Shareholders may determine. See “Plan of Distribution.”                                                                                                                                                                                                                                 |
| Ordinary shares issued and outstanding                                                |     | 84,819,996 ordinary shares (as of June 20, 2025) or 88,056,996 after giving effect to the exercise in full of the IR/PR Warrants. The foregoing number of shares outstanding does not give effect to the issuance of ordinary shares to A & M Construction pursuant to the Design-Build Agreement amendment.                                                                                                                                           |
| Use of proceeds                                                                       |     | All of the ordinary shares offered by the Selling Shareholders pursuant to this prospectus will be sold by the Selling Shareholders for their respective accounts. We will not receive any of the proceeds from these sales; however, we expect to receive approximately $12.26 million from the exercise of the IR/PR Warrants, assuming such IR/PR Warrants were exercised in full, unless such IR/PR Warrants were exercised on a “cashless” basis. |
| Dividend Policy                                                                       |     | We have never declared or paid any cash dividend on our ordinary shares. We currently intend to retain any future earnings and do not expect to pay any dividends in the foreseeable future. Any further determination to pay dividends on our ordinary shares would be at the discretion of our board of directors, subject to applicable laws, and would depend on our financial condition.                                                          |
| Market for our ordinary shares                                                        |     | Our ordinary shares are listed on the Nasdaq Stock Market LLC under the trading symbol “DRTS.”                                                                                                                                                                                                                                                                                                                                                         |
| Risk factors                                                                          |     | Prospective                                                                                                                                                                                                                                                                                                                                                                                                                                            
 investors should carefully consider the “Risk Factors